North America Proton Therapy Market By Type of System (Single Room System and Multi-Room System), By Application (Paediatric Cancer, Head & Neck Cancer, Prostate Cancer, Lung Cancer, Gastro-Intestinal Cancer, Brain Cancer and Others), By End-User (Hospitals, Radiotherapy Centres and Others) and Country  

North America Proton Therapy Market

Geographically North America proton therapy market is segmented into United States (U.S.) and Canada. U.S. proton therapy market is expected to grow at significant rates owing to the presence of global market players and growing adaptation of the proton therapy for the treatment of cancers. Cancer has a major impact on society in the United States in North America. The very common cancers are pancreatic cancer, breast cancer, colon and rectum cancer, prostate cancer, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, lung and bronchus cancer, leukaemia, thyroid cancer, and liver cancer. Each year in the United States, more than 1.6 million people are diagnosed with cancer, and almost 600,000 died from it, making it the second leading cause of death.

Canada proton therapy market is expected to have a notable growth rate over the forecast period due to the recent product approvals and growing adoption rates of the proton therapy. For instance, In February 2015, Mevion 250 proton system received medical device license from Health Canada, and it is first of its kind to receive the license from Health Canada.  The number of patients receiving proton therapy increased 176% from 2013 to 2022.

Geographically North America proton therapy market is segmented into United States (U.S.) and Canada. U.S. proton therapy market is expected to grow at significant rates owing to the presence of global market players and growing adaptation of the proton therapy for the treatment of cancers. Cancer has a major impact on society in the United States in North America. The very common cancers are pancreatic cancer, breast cancer, colon and rectum cancer, prostate cancer, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, lung and bronchus cancer, leukaemia, thyroid cancer, and liver cancer. Each year in the United States, more than 1.6 million people are diagnosed with cancer, and almost 600,000 died from it, making it the second leading cause of death.

Canada proton therapy market is expected to have a notable growth rate over the forecast period due to the recent product approvals and growing adoption rates of the proton therapy. For instance, In February 2015, Mevion 250 proton system received medical device license from Health Canada, and it is first of its kind to receive the license from Health Canada.  The number of patients receiving proton therapy increased 176% from 2013 to 2022.